Serum-Free Cell Culture Market Global Report 2026

The serum-free cell culture market size has grown rapidly in recent years. It will grow from $4.11 billion in 2025 to $4.66 billion in 2026 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to growing demand for biopharmaceutical production, increasing vaccine development activities, rising adoption of monoclonal antibody manufacturing, expanding regenerative medicine research, increasing investment in life sciences research.

The serum-free cell culture market size is expected to see rapid growth in the next few years. It will grow to $7.76 billion in 2030 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to growing commercialization of cell and gene therapies, increasing demand for scalable cell culture manufacturing, expanding biologics production capacity, rising adoption of advanced serum free formulations, increasing investments in bioprocess development. Major trends in the forecast period include growing adoption of chemically defined cell culture media, increasing demand for animal component free cell culture systems, rising use of xeno free media in advanced therapeutics, expansion of high yield cell culture processes, growing focus on reproducible and standardized cell culture workflows.

The growing demand for cell and gene therapies is anticipated to drive the growth of the serum-free cell culture market in the coming years. Cell and gene therapies are innovative medical treatments that utilize living cells or genetic materials to prevent, manage, or cure diseases by addressing their root causes. The increasing demand for cell and gene therapies is fueled by the rising burden of chronic and rare diseases, growing regulatory approvals, and increasing investments in regenerative medicine. Serum-free cell culture media facilitate the development and production of cell and gene therapies by offering a controlled, animal component-free environment that promotes cell growth, improves reproducibility, and reduces contamination risks, thereby supporting consistent product quality and adherence to regulatory standards. For instance, in July 2024, according to the American Society of Gene and Cell Therapy (ASGCT), a professional non-profit medical and scientific organization, 76 new gene therapy clinical trials were launched globally, representing a significant 25% increase compared to the previous quarter. Therefore, the increasing demand for cell and gene therapies is contributing to the growth of the serum-free cell culture market.

Leading companies operating in the serum-free cell culture market are focusing on developing chemically defined, serum-free, and animal-origin-free cell culture media to enhance cell therapy manufacturing, improve process consistency, and support regulatory compliance. Cell culture media are nutrient-rich formulations that provide the essential nutrients, growth factors, salts, and vitamins required to support the growth, maintenance, and proliferation of cells under controlled laboratory conditions. For example, in May 2023, Lonza Group Ltd., a Switzerland-based CDMO and life sciences company, launched the TheraPEAK T-VIVO Cell Culture Medium, a chemically defined, serum-free, and non-animal-origin medium designed to optimize CAR T-cell manufacturing and accelerate cell therapy development. It is formulated to support robust T-cell expansion while maintaining consistent cell growth and performance throughout the manufacturing process. Its chemically defined composition helps reduce variability associated with animal-derived components, improving process consistency and scalability. The launch expands Lonza's portfolio of cell and gene therapy manufacturing solutions, enabling developers to streamline process development and advance the commercialization of next-generation cell therapies.

In May 2023, Xcell Therapeutics, a South Korea-based company specializing in the development of serum-free chemically defined cell culture media, entered into a partnership with YiPSCELL to create specialized serum-free chemically defined media for induced pluripotent stem cells (iPSCs). Through this strategic collaboration, the companies intend to develop optimized culture media solutions for iPSC growth and further extend their partnership toward the production of artificial red blood cells utilizing iPSC technology. YiPSCELL is a South Korea-based biotechnology firm focused on induced pluripotent stem cell (iPSC)-based research and the development of therapeutic applications.

Major companies operating in the serum-free cell culture market report are Merck KGaA, Lonza Group AG, Sartorius AG, Avantor, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Corning Incorporated, Ajinomoto Co. Inc., GenScript Biotech Corporation, ACROBiosystems Co. Ltd., Sino Biological, HiMedia Laboratories Pvt. Ltd., PromoCell GmbH, Jianshun Biosciences Co. Ltd., REPROCELL Inc., Capricorn Scientific, Pan Biotech, ScienCell Research Laboratories, InVitria Inc., Cyagen Biosciences Inc., Nucleus Biologics LLC, OPM Biosciences, Qkine Ltd.

North America was the dominant region in the serum-free cell culture market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the serum-free cell culture market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the serum-free cell culture market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.